There are 2789 resources available
448P - Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice
Presenter: Mikhail Fedyanin
Session: ePoster Display
449P - Homologous recombination repair gene mutations predict the efficacy of immune checkpoint inhibitors therapy in colorectal cancer
Presenter: Yan Lin
Session: ePoster Display
450P - Efficacy and safety of pyrotinib-based therapy in HER2-positive metastatic colorectal and gastric cancer: A retrospective study
Presenter: qian Li
Session: ePoster Display
452P - Predicting response to bevacizumab in colorectal cancer by integrating radiomics to clinical and genomic features
Presenter: Gianluca Milanese
Session: ePoster Display
453P - Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre
Presenter: David Lau
Session: ePoster Display
454P - CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value
Presenter: Francesca Battaglin
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display